Discordant American College of Physicians and international rheumatology guidelines for gout management: consensus statement of the Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN)

[1]  L. Duley,et al.  OP0268 Nurse-led care versus general practitioner care of people with gout: a uk community-based randomised controlled trial , 2017 .

[2]  Hyon K. Choi,et al.  Trends in Gout and Rheumatoid Arthritis Hospitalizations in Canada From 2000 to 2011 , 2017, Arthritis care & research.

[3]  R. McLean.  The Long and Winding Road to Clinical Guidelines on the Diagnosis and Management of Gout , 2017, Annals of Internal Medicine.

[4]  T. Mikuls,et al.  To Treat or Not to Treat (to Target) in Gout , 2017, Annals of Internal Medicine.

[5]  P. Shekelle,et al.  Management of Gout: A Systematic Review in Support of an American College of Physicians Clinical Practice Guideline , 2017 .

[6]  A. Qaseem,et al.  Management of Acute and Recurrent Gout: A Clinical Practice Guideline From the American College of Physicians. , 2017, Annals of internal medicine.

[7]  J. Singh,et al.  Chasing crystals out of the body: will treat to serum urate target for gout help us get there? , 2016, Annals of the rheumatic diseases.

[8]  Hyon K. Choi,et al.  Editorial: Do Not Let Gout Apathy Lead to Gouty Arthropathy , 2016, Arthritis & rheumatology.

[9]  M. Weisman,et al.  Treat-to-target (T2T) recommendations for gout , 2016, Annals of the rheumatic diseases.

[10]  F. Becce,et al.  2016 updated EULAR evidence-based recommendations for the management of gout , 2014, Annals of the rheumatic diseases.

[11]  Hyon K. Choi,et al.  Trends in Gout and Rheumatoid Arthritis Hospitalizations in the United States, 1993-2011. , 2016, JAMA.

[12]  R. Terkeltaub,et al.  THU0537 Clinical Response of Tophus and Flares To Extended Use of Lesinurad in Combination with A Xanthine Oxidase Inhibitor in Patients with Gout , 2016 .

[13]  K. Saag,et al.  THU0495 Examination of Serum Uric Acid (Sua) Lowering and Safety with Extended Treatment with Lesinurad and Allopurinol in Subjects with Gout , 2016 .

[14]  M. Doherty,et al.  Comorbidities in patients with gout prior to and following diagnosis: case-control study , 2014, Annals of the rheumatic diseases.

[15]  N. Dalbeth,et al.  Factors influencing the crystallization of monosodium urate: a systematic literature review , 2015, BMC Musculoskeletal Disorders.

[16]  J. Singh,et al.  Erratum to: Comparative effectiveness of urate lowering with febuxostat versus allopurinol in gout: analyses from large U.S. managed care cohort , 2015, Arthritis Research & Therapy.

[17]  陳建勳,et al.  Use of HLA-B*58:01 genotyping to prevent allopurinol induced severe cutaneous adverse reactions in Taiwan: national prospective cohort study , 2015 .

[18]  W. Taylor,et al.  An Observational Study of Gout Prevalence and Quality of Care in a National Australian General Practice Population , 2015, The Journal of Rheumatology.

[19]  Hyon K. Choi,et al.  Flare frequency, healthcare resource utilisation and costs among patients with gout in a managed care setting: a retrospective medical claims-based analysis , 2015, BMJ Open.

[20]  P. Clerson,et al.  Revisiting comorbidities in gout: a cluster analysis , 2013, Annals of the Rheumatic Diseases.

[21]  Hyon K. Choi,et al.  Cost-Effectiveness of Allopurinol and Febuxostat for the Management of Gout , 2014, Annals of Internal Medicine.

[22]  W. Taylor,et al.  Toward Development of a Tophus Impact Questionnaire: A Qualitative Study Exploring the Experience of People With Tophaceous Gout , 2014, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.

[23]  J. Singh.  The impact of gout on patient’s lives: a study of African-American and Caucasian men and women with gout , 2014, Arthritis Research & Therapy.

[24]  N. Dalbeth,et al.  Exploratory Study of Radiographic Change in Patients With Tophaceous Gout Treated With Intensive Urate‐Lowering Therapy , 2014, Arthritis care & research.

[25]  C. Bombardier,et al.  Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative , 2013, Annals of the rheumatic diseases.

[26]  Mei‐Ling Yeh.  Achieving knowledge translation in nursing care: the need for greater rigor in applying evidence to practice. , 2014, The journal of nursing research : JNR.

[27]  F. Ottery,et al.  Tophus burden reduction with pegloticase: results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapy , 2013, Arthritis Research & Therapy.

[28]  Hyon K. Choi,et al.  Managing gout needs more than drugs: ‘Il faut le savoir-faire, l'Art et la manière’ , 2013, Annals of the rheumatic diseases.

[29]  Michael Pignone,et al.  How to decide whether a clinical practice guideline is trustworthy. , 2013, JAMA.

[30]  F. Ottery,et al.  Long-term safety of pegloticase in chronic gout refractory to conventional treatment , 2012, Annals of the rheumatic diseases.

[31]  M. Doherty,et al.  Patients with gout adhere to curative treatment if informed appropriately: proof-of-concept observational study , 2012, Annals of the rheumatic diseases.

[32]  D. Khanna.  American College of Rheumatology guidelines for management of gout , 2013 .

[33]  R. Terkeltaub,et al.  2012 American College of Rheumatology guidelines for management of gout. Part 2: Therapy and antiinflammatory prophylaxis of acute gouty arthritis , 2012, Arthritis care & research.

[34]  Charles King,et al.  2012 American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia , 2012, Arthritis care & research.

[35]  D. Khanna,et al.  Tophi and frequent gout flares are associated with impairments to quality of life, productivity, and increased healthcare resource use: Results from a cross-sectional survey , 2012, Health and Quality of Life Outcomes.

[36]  W. Taylor,et al.  Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol. , 2012, Arthritis and rheumatism.

[37]  J. Singh,et al.  Improved Health-related Quality of Life and Physical Function in Patients with Refractory Chronic Gout Following Treatment with Pegloticase: Evidence from Phase III Randomized Controlled Trials , 2012, The Journal of Rheumatology.

[38]  K. Rascati,et al.  Evaluation of health care costs and utilization patterns for patients with gout. , 2012, Clinical therapeutics.

[39]  W. White,et al.  Pegloticase and Chronic Gout—Reply , 2011 .

[40]  P. Lipsky,et al.  Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. , 2011, JAMA.

[41]  P. Shekelle,et al.  The Development of Clinical Practice Guidelines and Guidance Statements of the American College of Physicians: Summary of Methods , 2010, Annals of Internal Medicine.

[42]  Jillian Cornish,et al.  Cellular characterization of the gouty tophus: a quantitative analysis. , 2010, Arthritis and rheumatism.

[43]  H. Schumacher,et al.  The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial , 2010, Arthritis research & therapy.

[44]  M. Fuldeore,et al.  Impact of noncompliance with urate-lowering drug on serum urate and gout-related healthcare costs: administrative claims analysis* , 2009, Current medical research and opinion.

[45]  H. Schumacher,et al.  Clinical Efficacy and Safety of Successful Longterm Urate Lowering with Febuxostat or Allopurinol in Subjects with Gout , 2009, The Journal of Rheumatology.

[46]  S. Nicolaou,et al.  Dual energy computed tomography in tophaceous gout , 2008, Annals of the rheumatic diseases.

[47]  H. Schumacher,et al.  Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study. , 2008, Rheumatology.

[48]  G. Gamble,et al.  Mechanisms of bone erosion in gout: a quantitative analysis using plain radiography and computed tomography , 2008, Annals of the rheumatic diseases.

[49]  H. Schumacher,et al.  Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. , 2008, Arthritis and rheumatism.

[50]  J. Avorn,et al.  Uric acid lowering therapy: prescribing patterns in a large cohort of older adults , 2007, Annals of the rheumatic diseases.

[51]  F. Perez-Ruiz,et al.  Ultrasonographic measurement of tophi as an outcome measure for chronic gout. , 2007, The Journal of rheumatology.

[52]  E. Pascual,et al.  Time required for disappearance of urate crystals from synovial fluid after successful hypouricaemic treatment relates to the duration of gout , 2007, Annals of the rheumatic diseases.

[53]  J. Stockman,et al.  Febuxostat Compared with Allopurinol in Patients With Hyperuricemia and Gout , 2007 .

[54]  B. Thiers.  HLA-B*5801 Allele as a Genetic Marker for Severe Cutaneous Adverse Reactions Caused by Allopurinol , 2006 .

[55]  F. Perez-Ruiz,et al.  Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. , 2002, Arthritis and rheumatism.

[56]  H. Schumacher,et al.  Treatment of chronic gout. Can we determine when urate stores are depleted enough to prevent attacks of gout? , 2001, The Journal of rheumatology.

[57]  J. Pijoan,et al.  Improvement of Renal Function in Patients with Chronic Gout after Proper Control of Hyperuricemia and Gouty Bouts , 2000, Nephron.

[58]  D. Sackett,et al.  Evidence based medicine: what it is and what it isn't , 1996, BMJ.

[59]  W. Downie,et al.  Observations on spontaneous improvement in patients with podagra: implications for therapeutic trials of non-steroidal anti-inflammatory drugs. , 1987, British journal of clinical pharmacology.

[60]  R Turner,et al.  REAL-TIME CARDIAC IMAGING OF ADULTS AT VIDEO FRAME RATES BY MAGNETIC RESONANCE IMAGING , 1986, The Lancet.

[61]  G. H. Nancollas,et al.  The crystallization and dissolution of sodium urate , 1981 .

[62]  H. Schumacher.  Pathology of the synovial membrane in gout , 1975 .

[63]  H. Schumacher.  Pathology of the synovial membrane in gout. Light and electron microscopic studies. Interpretation of crystals in electron micrographs. , 1975, Arthritis and rheumatism.

[64]  A. Gutman.  The past four decades of progress in the knowledge of gout, with an assessment of the present status. , 1973, Arthritis and rheumatism.

[65]  J. Loeb.  The influence of temperature on the solubility of monosodium urate. , 1972, Arthritis and rheumatism.

[66]  D. Mccarty.  A historical note: Leeuwenhoek's description of crystals from a gouty tophus. , 1970, Arthritis and rheumatism.

[67]  J. Seegmiller.  The acute attack of gouty arthritis. , 1965, Arthritis and rheumatism.

[68]  D. Mccarty,et al.  ACUTE ARTHRITIS IN MAN AND DOG AFTER INTRASYNOVIAL INJECTION OF SODIUM URATE CRYSTALS , 1962 .

[69]  D. Mccarty,et al.  Identification of urate crystals in gouty synovial fluid. , 1961, Annals of internal medicine.

[70]  P. Hench.  DIAGNOSIS AND TREATMENT OF GOUT AND GOUTY ARTHRITIS , 1941 .